IQWiG finds no added benefit for Dendreon's Provenge or Gilead's Zydelig
This article was originally published in Scrip
Executive Summary
There is no proven benefit for either Dendreon's prostate cancer treatment Provenge (Sipuleucel-T) or Gilead's Zydelig (idelalisib) for follicular lymphoma or chronic lymphocytic leukaemia, according to IQWiG, Germany's health technology appraisal body.